97. Ulcerative colitis Clinical trials / Disease details

Clinical trials : 2,527 /  Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04898348
(ClinicalTrials.gov)		August 202113/5/2021A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative ColitisA Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative ColitisUlcerative ColitisDrug: Vancomycin Pre-Treatment;Drug: KBL697;Drug: PlaceboKoBioLabsNULLNot yet recruiting18 Years75 YearsAll30Phase 2NULL
2NCT03759041
(ClinicalTrials.gov)		December 19, 201827/11/2018A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative ColitisECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative ColitisUlcerative ColitisDrug: Vancomycin Pre-Treatment;Drug: Placebo for Vancomycin Pre-Treatment;Drug: SER-287;Drug: Placebo for SER-287Seres Therapeutics, Inc.NULLTerminated18 Years80 YearsAll203Phase 2United States;Canada
3NCT02618187
(ClinicalTrials.gov)		January 13, 201620/11/2015A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative ColitisA Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative ColitisUlcerative ColitisDrug: SER-287;Drug: Placebo;Drug: Placebo Pre-Treat;Drug: Vancomycin Pre-TreatSeres Therapeutics, Inc.NULLCompleted18 Years75 YearsAll58Phase 1United States